Kamposioras Konstantinos, Mauri Davide, Papadimitriou Konstantinos, Anthoney Alan, Hindi Nadia, Petricevic Branka, Dambrosio Mario, Valachis Antonis, Kountourakis Pantelis, Kopecky Jindrich, Kuhar Cvetka Grašič, Popovic Lazar, Chilingirova Nataliya P, Zarkavelis George, de Mello Ramon Andrade, Plavetić Natalija Dedić, Christopoulos Christos, Mostert Bianca, Goffin John R, Tzachanis Dimitiros, Saraireh Haytham Hamed, Ma Fei, Pavese Ida, Tolia Maria
Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom.
Department of Medical Oncology, University Hospital of Ioannina, Ioannina, Greece.
Front Oncol. 2020 Nov 19;10:575148. doi: 10.3389/fonc.2020.575148. eCollection 2020.
Pandemic COVID-19 is an unexpected challenge for the oncological community, indicating potential detrimental effects on cancer patients. Our aim was to summarize the converging key points providing a general guidance in order to support decision making, pertaining to the oncologic care in the middle of a global outbreak.
We did an international online search in twenty five countries that have managed a surge in cancer patient numbers. We collected the recommendations from thirty one medical oncology societies.
By synthesizing guidelines for a) oncology service delivery adjustments, b) general and specific treatment adaptations, and c) discrepancies from guidelines comparison, we present a clinical synopsis with the forty more crucial statements. A Covid-19 risk stratification base was also created in order to obtain a quick, objective patient assessment and a risk-benefit evaluation on a case-by-case basis.
In an attempt to face these complex needs and due to limited understanding of COVID-19, a variability of recommendations based on general epidemiological and infectious disease principles rather than definite cancer-related evidence has evolved. Additionally, the absence of an effective treatment or vaccine requires the development of cancer management guidance, capitalizing on comprehensive COVID-19 oncology experience globally.
新冠疫情大流行对肿瘤学界来说是一个意想不到的挑战，显示出对癌症患者可能产生的有害影响。我们的目的是总结一些共同的关键点，提供一般性指导，以支持在全球疫情爆发期间有关肿瘤护理的决策。
我们在25个癌症患者数量激增的国家进行了国际在线搜索。我们收集了31个医学肿瘤学会的建议。
通过综合关于a）肿瘤服务提供调整、b）一般和特殊治疗调整以及c）指南比较差异的指南，我们给出了一份包含40多条关键陈述的临床概要。还建立了一个新冠风险分层基础，以便快速、客观地评估患者，并逐案进行风险效益评估。
由于对新冠疫情了解有限，为应对这些复杂需求，基于一般流行病学和传染病原则而非明确的癌症相关证据的建议出现了差异。此外，由于缺乏有效的治疗方法或疫苗，需要利用全球范围内全面的新冠肿瘤学经验来制定癌症管理指南。
